Torrent Pharma Derma Products

All information provided on this web site (www.OddwayInternational.com) property of 'Oddway International' is provided for information purposes only and does not constitute a legal contract between this site and any person or entity unless otherwise specified. Information on this site is subject to change without prior notice. Although every reasonable effort is made to present current and accurate information, the site makes no guarantees of any kind. The web site may contain information (including but not limited to medical content, images, videos, blogs and news articles) that is created and maintained by a variety of sources both internal and external to it. These internal urls / sites are unmoderated forums containing the personal opinions and other expressions of the persons who post the content / entries. The site does not control, monitor or guarantee the information contained in these internal urls / sites or information contained in links to other external web sites, and does not endorse any views expressed or products or services offered therein.

In no event shall the site be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any such content, goods, or services available on or through any such site or resource. Amibroker crack blogspot. This site does not provide any medical advise and the content of this site should not be a substitute for professional medical advise, diagnosis or any treatment.

Ahmedabad based Torrent Pharma enters New Year 2016 by announcing the launch of biosimilar Adalimumab in India under the brand name 'Adfrar'. Adalimumab is the most preferred therapy for the treatment of auto immune disorders and has wide applications like Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis and Plaque Psoriasis. Adalimumab is the largest selling drug across the globe (innovator brand Humira has sales of 15 billion USD). Torrent's brand 'Adfrar' will be the second biosimilar Adalimumab in the world. Autoimmune disorders are growing ailments and Monoclonal Antibodies (MAb's) are becoming mainstay of treatment, therefore launch of 'Adfrar' is a significant step towards fortifying its presence in MAb market.

Biosimilar Rituximab - 'Toritz RA' is already launched in Rheumatology segment and now with launch of biosimilar Adalimumab - 'Adfrar', Torrent presence in this segment will get a major fillip, making it a significant player in this super speciality. 'Adfrar' will be available as Pre Filled Syringe of 40mg. Torrent will promote this biosimilar to Rheumatologists, Gastroenterologists and Dermatologists pan India, for which three separate super specialty task force have been introduced. Around 100 highly trained professionals are employed in these Greenfield divisions. About Torrent India Torrent is amongst the top 20 companies in India with over 23% growth on MAT Nov'15 basis and currently ranked 16th. In addition to 14 divisions in India business with over 2000 Crores turnover, three new super specialty teams have been introduced. The GI super speciality team, besides promoting biosimilar Adalimumab – 'Adfrar IB' to Gastroenterologists, will also cater to the advanced therapy needs in Hepatology.

Torrent has launched new generation Hep C Antiviral Sofosbuvir - 'Sofocruz', a combination of Sofosbuvir + Ledipasvir - 'Sofocruz LP' and Daclatasvir - 'Daclacruz'. Moreover, the company has also launched Hep B Antiviral Tenofovir - 'Tenocruz'.

Torrent is already marketing biosimilar Rituximab - 'Toritz' in Oncology segment, while a super specialty division for Nephrology was also launched in 2014 with the launch of biosimilar Darbepoetin alpha - 'Darbatitor'. The focus of Torrent Pharma India is never with business intent alone, rather it is a by product. The primary goal has always been to launch specialty niche products to address unmet medical needs arising from major life threatening diseases and reach out to maximum number of patients to offer cost effective treatment with latest quality drugs. With introduction of these new super specialty divisions, Torrent Pharma now covers most of the specialties and in near future plans to enter Urology and Ophthalmology segments to cover the therapy gaps with strategic fit products. About Torrent: Torrent Pharma, with annual revenues of almost Rs.

All information provided on this web site (www.OddwayInternational.com) property of 'Oddway International' is provided for information purposes only and does not constitute a legal contract between this site and any person or entity unless otherwise specified. Information on this site is subject to change without prior notice. Although every reasonable effort is made to present current and accurate information, the site makes no guarantees of any kind. The web site may contain information (including but not limited to medical content, images, videos, blogs and news articles) that is created and maintained by a variety of sources both internal and external to it. These internal urls / sites are unmoderated forums containing the personal opinions and other expressions of the persons who post the content / entries. The site does not control, monitor or guarantee the information contained in these internal urls / sites or information contained in links to other external web sites, and does not endorse any views expressed or products or services offered therein.

In no event shall the site be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any such content, goods, or services available on or through any such site or resource. Amibroker crack blogspot. This site does not provide any medical advise and the content of this site should not be a substitute for professional medical advise, diagnosis or any treatment.

Ahmedabad based Torrent Pharma enters New Year 2016 by announcing the launch of biosimilar Adalimumab in India under the brand name 'Adfrar'. Adalimumab is the most preferred therapy for the treatment of auto immune disorders and has wide applications like Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis and Plaque Psoriasis. Adalimumab is the largest selling drug across the globe (innovator brand Humira has sales of 15 billion USD). Torrent's brand 'Adfrar' will be the second biosimilar Adalimumab in the world. Autoimmune disorders are growing ailments and Monoclonal Antibodies (MAb's) are becoming mainstay of treatment, therefore launch of 'Adfrar' is a significant step towards fortifying its presence in MAb market.

Biosimilar Rituximab - 'Toritz RA' is already launched in Rheumatology segment and now with launch of biosimilar Adalimumab - 'Adfrar', Torrent presence in this segment will get a major fillip, making it a significant player in this super speciality. 'Adfrar' will be available as Pre Filled Syringe of 40mg. Torrent will promote this biosimilar to Rheumatologists, Gastroenterologists and Dermatologists pan India, for which three separate super specialty task force have been introduced. Around 100 highly trained professionals are employed in these Greenfield divisions. About Torrent India Torrent is amongst the top 20 companies in India with over 23% growth on MAT Nov'15 basis and currently ranked 16th. In addition to 14 divisions in India business with over 2000 Crores turnover, three new super specialty teams have been introduced. The GI super speciality team, besides promoting biosimilar Adalimumab – 'Adfrar IB' to Gastroenterologists, will also cater to the advanced therapy needs in Hepatology.

Torrent has launched new generation Hep C Antiviral Sofosbuvir - 'Sofocruz', a combination of Sofosbuvir + Ledipasvir - 'Sofocruz LP' and Daclatasvir - 'Daclacruz'. Moreover, the company has also launched Hep B Antiviral Tenofovir - 'Tenocruz'.

Torrent is already marketing biosimilar Rituximab - 'Toritz' in Oncology segment, while a super specialty division for Nephrology was also launched in 2014 with the launch of biosimilar Darbepoetin alpha - 'Darbatitor'. The focus of Torrent Pharma India is never with business intent alone, rather it is a by product. The primary goal has always been to launch specialty niche products to address unmet medical needs arising from major life threatening diseases and reach out to maximum number of patients to offer cost effective treatment with latest quality drugs. With introduction of these new super specialty divisions, Torrent Pharma now covers most of the specialties and in near future plans to enter Urology and Ophthalmology segments to cover the therapy gaps with strategic fit products. About Torrent: Torrent Pharma, with annual revenues of almost Rs.